Inroads in the therapy of indolent lymphomas: exploiting biological insights.
McLaughlin
P
P
Department of Lymphoma-Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, USA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017209:Apoptosis; D014408:Biomarkers, Tumor / Q000032:analysis; D019090:Case Management; D002986:Clinical Trials as Topic; D019254:Genes, bcl-2; D006801:Humans; D007155:Immunologic Factors; D016898:Interferon-alpha / Q000627:therapeutic use; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D015182:Lymphatic Irradiation; D008228:Lymphoma, Non-Hodgkin / Q000145:classification / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016133:Polymerase Chain Reaction; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000502:physiology; D016499:Radioimmunotherapy; D012074:Remission Induction; D016019:Survival Analysis; D014178:Translocation, Genetic
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D007155:Immunologic Factors; D016898:Interferon-alpha; D007457:Iodine Radioisotopes; D019253:Proto-Oncogene Proteins c-bcl-2